Retinal Redetachment After Silicone Oil Removal : a Risk Factor Analysis
Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Dec 4, 2022
Trial Information
Current as of February 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients with successfully repaired rhegmatogenous retinal detachment and subsequent silicone oil removal
- • minimum follow-up period of 6 months after silicone oil removal
- Exclusion Criteria:
- • Silicone oil tamponade for indications other than rhegmatogenous retinal detachment
- • Retinal redetachment during silicone oil tamponade
- • Prior history of silicone oil tamponade
About Central Hospital, Nancy, France
Central Hospital, located in Nancy, France, is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes. As a prominent clinical trial sponsor, the hospital is committed to conducting innovative studies across various therapeutic areas, fostering collaboration among multidisciplinary teams of healthcare professionals and researchers. With a strong emphasis on ethical standards and patient safety, Central Hospital leverages its state-of-the-art facilities and expertise to contribute to the development of cutting-edge treatments and enhance the overall quality of care within the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vandœuvre Lès Nancy, , France
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials